MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Fate Therapeutics Inc

Closed

SectorHealthcare

1.14 4.59

Overview

Share price change

24h

Current

Min

1.09

Max

1.16

Key metrics

By Trading Economics

Income

15M

-38M

Sales

-231K

1.6M

Profit margin

-2,309.454

Employees

181

EBITDA

4.3M

-38M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+348.62% upside

Dividends

By Dow Jones

Next Earnings

11 sie 2025

Market Stats

By TradingEconomics

Market Cap

5.8M

128M

Previous open

-3.45

Previous close

1.14

News Sentiment

By Acuity

58%

42%

322 / 376 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 lip 2025, 15:46 UTC

Major Market Movers

BitMine Shares Fall After Closing of $250 Million Private Placement

9 lip 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 lip 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 lip 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 lip 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 lip 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 lip 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 lip 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lip 2025, 20:26 UTC

Earnings

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 lip 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 lip 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 lip 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 lip 2025, 17:07 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 lip 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 lip 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 lip 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 lip 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 lip 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 lip 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 lip 2025, 16:14 UTC

Acquisitions, Mergers, Takeovers

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 lip 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 lip 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 lip 2025, 15:31 UTC

Major Market Movers

BitMine Shares Fall After Closing of $250M Private Placement

9 lip 2025, 15:31 UTC

Market Talk
Acquisitions, Mergers, Takeovers

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 lip 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 lip 2025, 14:36 UTC

Acquisitions, Mergers, Takeovers

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 lip 2025, 14:31 UTC

Acquisitions, Mergers, Takeovers

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 lip 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 lip 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

348.62% upside

12 Months Forecast

Average 4.89 USD  348.62%

High 12 USD

Low 2 USD

Based on 10 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

10 ratings

2

Buy

8

Hold

0

Sell

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

322 / 376 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.